The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...
"Overall, metabolic responses to glucagon stimulation in individuals with type 1 diabetes are comparable to those in healthy ...
Several years ago, a little-known drug named Ozempic — previously used only to treat diabetes — emerged as a promising new ...
The digital health unicorn sells its chronic condition management and musculoskeletal programs to employers and health plans ...
Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...
Sometimes, the conversation doesn’t get past a handful of words, and just the attempt may threaten the patient-physician ...
In a ginormous new study, researchers have begun mapping the manifold health benefits of drugs like Ozempic and Wegovy beyond ...
They also don’t directly support behavior change, which Kathryn Ilonka Pollak, PhD, a professor in population health sciences ...
Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing ...
A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback